Previous 10 | Next 10 |
NRx Pharmaceuticals to Present at the Sidoti Virtual Small Cap Conference PR Newswire RADNOR, Pa. , Sept. 18, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today a...
NRX Pharmaceuticals Announces Data Sharing Agreement Demonstrating Efficacy and Safety of Intravenous Ketamine for the Treatment of Suicidal Bipolar Depression PR Newswire Ketamine, an NMDA blocker, was highly effective in Bipolar subgroup (p<0.001) NRx plans to p...
NRx Pharmaceuticals Announces Agreement with LifeSci Associates to Provide Financial Services and Support PR Newswire Industry veteran Richard Narido joins the NRx Pharmaceuticals management team RADNOR, Pa. , Sept. 14, 2023 /PRNewswire/ -- NRx Ph...
NRx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference PR Newswire RADNOR, Pa. , Sept. 7, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharma...
NRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary Pathogens PR Newswire NRX-101 demonstrated potent antibacterial effect against antibiotic-resistant pathogens in culture medium and in an artificial urine mode...
NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain PR Newswire IND builds on previously-published, preliminary evidence of efficacy Filing is supported by robust manufacturing, pre-cl...
NRx Pharmaceuticals Announces Definitive Purchase Agreement for Preferred Shares at $0.40 per share PR Newswire NRx Pharmaceuticals received approximately $1.2 million in cash from existing investors Preferred shares to sold at $0.40 ; shares convert to...
2023-08-14 21:58:04 ET NRX Pharmaceuticals, Inc. (NRXP) Q2 2023 Earnings Conference Call August 14, 2023, 16:30 ET Company Participants Matthew Duffy - Chief Business Officer Steve Willard - CEO & Director Jonathan Javitt - Chief Scientist & Director ...
2023-08-14 16:20:40 ET More on NRx Pharmaceuticals NRx says FDA suggests broadening use of bipolar depression disorder drug in trial NRx Pharma gains on FDA comments regarding lead asset NRx Pharma gains as Phase 3 trial for bipolar candidate starts Relief, N...
NRx Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update PR Newswire Two near-term data catalysts expected in 2023 Entered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development an...
News, Short Squeeze, Breakout and More Instantly...
NRX Pharmaceuticals Inc. Company Name:
NRXP Stock Symbol:
NASDAQ Market:
NRX Pharmaceuticals Inc. Website:
NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing PR Newswire New Drug Application (NDA) for Accelerated Approval planned for NRX-101 in people with bipolar depression and akathisia in 202...
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024 PR Newswire RADNOR, Pa. , June 20, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals"...
NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Neuroscience, Information Technology and Medical Technology Veteran to its Board of Directors PR Newswire Dr. Dennis McBride brings extensive experience in Neuroscience and its interface with Information and Medical Technology ...